| Name | Vaniprevir |
|---|---|
| Synonyms |
Cyclopropanecboxamide, N-[[[6-(2-cboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethyl-, (1→2)-lactone, (1R,2R)
MK 7009/Vaniprevir (1R,2R)-N-[[[6-(2-Cboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethylcyclopropanecboxamide -lactone Vaniprevir(MK-7009) MK-7009;MK7009;MK |
| Description | Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.IC50 Value: Target: HCV NS3/4A Protease; HCVvaniprevir (MK-7009) is a macrocyclic hepatitis C virus NS3/4a protease inhibitor, is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes. vaniprevir (MK-7009) has good plasma exposure and excellent liver exposure in multiple species. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.33g/cm3 |
|---|---|
| Molecular Formula | C38H55N5O9S |
| Molecular Weight | 757.93600 |
| Exact Mass | 757.37200 |
| PSA | 197.59000 |
| LogP | 5.27350 |